Author

L. Andersch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Kuenkele· 2 shared A. Eggert· 1 shared A. G. Henssen· 1 shared A. Klaus· 1 shared A. Pruss· 1 shared A. Vitali· 1 shared C. Caramel· 1 shared C. E. Porter· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Kuenkele

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

L. Grunewald, L. Andersch, K. Helmsauer, S. Schwiebert, A. Klaus, A. G. Henssen, T. Straka, M. Lodrini, S. G. Wicha, S. Fuchs, F. Hertwig, F. Westermann, A. Vitali, C. Caramel, G. Buechel, , A. Kuenkele

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

bioRxiv · Jan 27, 2024Immunology

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

J. Kath, C. Franke, V. Drosdek, W. Du, V. Glaser, C. Fuster-Garcia, M. Stein, T. Zittel, S. Schulenberg, C. E. Porter, L. Andersch, A. Kuenkele, J. Alcaniz, J. Hoffmann, H. Abken, , D. L. Wagner

This paper develops a method to integrate ζ-deficient CARs into the CD3ζ gene to create functional CAR-T and CAR-NK cells with improved safety and efficacy for off-the-shelf therapies.

bioRxiv · Nov 10, 2023 · PreprintImmunology